ROSSARI BIOTECH LIMITEDRecord revenue ₹698 Cr, EBITDA ₹87 Cr, Saudi site

Rossari Biotech's Q2 FY27 call, held on 19 October 2026, reported record revenue of ₹697.6 crore, up 19%, and record EBITDA of ₹87 crore, up 21%, at a margin of 12.5%.

Gross margin recovered to 31.6% on better mix, but the core B2B EBITDA margin fell to 14.1% from 14.8% as freight costs doubled or tripled and phenol rose. The institutional and B2C business reached EBITDA break-even and management plans to exit non-core businesses at the right value. Exports were 31% of revenue, textile specialty grew 26%, net debt fell to ₹221 crore and working capital improved to 86 days. The Board approved leasing land in Saudi Arabia through a wholly owned subsidiary, though no cost or timeline was given.

Management guided to an EBITDA margin near 12% and mid- to high-teen revenue growth for FY27, said ethylene oxide supply from Reliance is the volume constraint until its expansion in Q1 next year, and would not forecast H2 because of Middle East shipping risks.